File: A researcher at CS/ECE wears a lab coat.
Researchers at Cedars-Sinai have moved a step closer to better treatment of arthritis, diabetes and a number of other diseases caused in part by inflammation, and it all starts with a tiny molecule.
The new finding may help create medications that will stop our bodies from over-producing a molecule called “interluekin-1 beta.” That molecule is a contributor to Type 2 diabetes, rheumatoid arthritis, some strokes and heart disease.
Until now, treatment focused on blocking the molecule only after our bodies created it.
But Cedars-Sinai researchers say they now have a better understanding of how the body produces the molecule in the first place — an important step toward new medications that will stop the molecule’s production before it starts, leading to better treatment of inflammatory diseases that affect an estimated 100 million Americans.